Overview

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Treatments:
Bleomycin
Cyclophosphamide
Epoetin Alfa
Prednisone
Vincristine